STRM.BIO
MA - CambridgeBiotechnology
Focus: STRM.BIO is an early-stage biotech company developing extracellular vesicle (EV)-based platforms to deliver gene therapies, with initial focus in oncology. The company is pre-revenue and pre-clinical stage.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Open Jobs
1-1 this month
Stable — net -1 jobs in 30d
0 added, 1 removed. Backfill posture.
Should You Work at STRM.BIO?
AI assessmentSTRM.BIO is a speculative, high-risk opportunity best suited for scientists seeking platform-building experience and equity exposure rather than job security or established product portfolios.
Why Work Here
- Cutting-edge platform technology (extracellular vesicles) with significant unmet potential in gene delivery—a high-risk, high-reward scientific opportunity
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for STRM.BIO
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.